329 completed, 201 recruiting, 107 terminated, 83 unknown. 771 Phase 1, 202 Phase 2, 18 Early Phase 1, 9 Not applicable, 2 Phase 3.
Follow Advanced Solid Tumors: new trials by email Literature Review of Advanced Solid Tumors trials Research Report on Advanced Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CHO-A04 in Advanced Solid Tumors CHO-A04 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Cho Pharma Inc. | 62 | 2027-07-01 | 2026-10-22 |
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2026-12-01 | 2026-08-04 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| A Clinical Trial to Evaluate the Safety and Tolerability of SYS6077 Injection in Participants With Advanced Malignant Tumor SYS6077 - Advanced Solid Tumors | Phase 1 | Not yet recruiting | Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | 110 | 2026-11-22 | 2026-10-14 |
| A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) MK-2750, 5-HT3 serotonin receptor antagonist, NK-1 receptor antagonist - Advanced Solid Tumors, Malignant Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 300 | 2026-11-16 | 2026-10-15 |
| A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn BNT3210 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | BioNTech SE | 173 | 2026-11-01 | 2026-10-21 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-27 | 2026-10-08 |
| A Study of DXC018 in Patients With Advanced Solid Tumors DXC018 - Advanced Solid Tumors | Phase 1 | Not yet recruiting | Hangzhou DAC Biotechnology Co., Ltd. | 110 | 2026-10-18 | 2026-09-30 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors SYS6043, bevacizumab, carboplatin - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 400 | 2026-10-15 | 2026-09-22 |
| A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors LCB02A - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | LigaChem Biosciences, Inc. | 191 | 2026-10-14 | 2026-10-19 |
| A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist - Advanced Solid Tumors, Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 200 | 2026-10-07 | 2026-10-15 |
| A Study of AK157D1 for Injection in Advanced Solid Tumors AK157D1 for injection - Advanced Solid Tumors | Phase 1 | Recruiting | Akeso | 243 | 2026-09-30 | 2026-10-13 |
| An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors SG1827, anti-PD-1/PD-L1 antibody, bevacizumab - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Hangzhou Sumgen Biotech Co., Ltd. | 180 | 2026-09-22 | 2026-08-19 |
| Phase I Study of SM2275 Injection in Patients With Advanced Solid Tumors SM2275 - Advanced Solid Tumors | Phase 1 | Not yet recruiting | Beijing StarMab Biomed Technology Ltd | 72 | 2026-09-20 | 2026-09-08 |
| A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors ABBV-253 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Recruiting | AbbVie | 130 | 2026-09-14 | 2026-10-16 |
| A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors HW221043 Tablets - Advanced Solid Tumors | Phase 1 | Recruiting | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | 99 | 2026-09-10 | 2026-09-11 |
| Safety and Activity of HF50 in Patients With Advanced Solid Tumors HF50 - Advanced Solid Tumors | Phase 1 | Recruiting | HighField Biopharmaceuticals Corporation | 45 | 2026-09-08 | 2026-09-28 |
| NK Cell Injection for Advanced Solid Tumors NK CELLS - Advanced Solid Tumors | Phase 1 | Not yet recruiting | BOE Technology Group Co., Ltd. | 9 | 2026-09-01 | 2026-08-25 |
| A Study of IOV-5001 in Adults With Advanced Solid Tumors IOV-5001 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Iovance Biotherapeutics, Inc. | 106 | 2026-09-01 | 2026-09-15 |
| SKB565 for Injection in Advanced Solid Tumors SKB565 - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 180 | 2026-08-31 | 2026-09-03 |
Showing 20 of 838. Sign in to see all of them.
Neoplasms (112) · Carcinoma, Non-Small-Cell Lung (72) · Colorectal Neoplasms (63) · Breast Neoplasms (41) · Neoplasm Metastasis (41) · Ovarian Neoplasms (36) · Pancreatic Neoplasms (31) · Lymphoma (29) · Melanoma (28) · Squamous Cell Carcinoma of Head and Neck (28) · Stomach Neoplasms (26) · Triple Negative Breast Neoplasms (21) · Carcinoma, Renal Cell (17) · Endometrial Neoplasms (17) · Uterine Cervical Neoplasms (17)
Neoplasms (197) · Neoplasms by Site (180) · Neoplasms by Histologic Type (142) · Digestive System Diseases (106) · Digestive System Neoplasms (105) · Neoplasms, Glandular and Epithelial (83) · Respiratory Tract Diseases (82) · Respiratory Tract Neoplasms (82) · Gastrointestinal Diseases (81) · Lung Diseases (81) · Thoracic Neoplasms (81) · Bronchial Neoplasms (78) · Carcinoma, Bronchogenic (78) · Skin Diseases (78) · Skin and Connective Tissue Diseases (78)
pembrolizumab (42) · Carboplatin (37) · Injections (33) · Paclitaxel (28) · Bevacizumab (26) · Docetaxel (26) · Cisplatin (23) · Nivolumab (20) · Fluorouracil (17) · Gemcitabine (17) · Oxaliplatin (16) · Pemetrexed (15) · Cetuximab (14) · Leucovorin (14) · Capecitabine (13)
Novartis Pharmaceuticals (22) · Pfizer (20) · Bristol-Myers Squibb (19) · Amgen (17) · Merck Sharp & Dohme LLC (17) · Millennium Pharmaceuticals, Inc. (14) · Jiangsu HengRui Medicine Co., Ltd. (13) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (12) · AbbVie (11) · MedImmune LLC (11) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (11) · Astellas Pharma Global Development, Inc. (10) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (10) · AstraZeneca (9) · Qilu Pharmaceutical Co., Ltd. (9)
United States (400) · China (305) · Spain (105) · Australia (96) · South Korea (66) · Canada (65) · United Kingdom (65) · France (63) · Japan (55) · Italy (47) · Netherlands (37) · Taiwan (37) · Belgium (36) · Switzerland (36) · Germany (30)
Lin Shen (5) · Mark D. McKee, MD (4)
PMID 25749986, PMID 29158363, PMID 30120268, PMID 32816849, PMID 35596791, PMID 18729192, PMID 19900802, PMID 23429330, PMID 23591447, PMID 23903897, PMID 24241212, PMID 24252402, PMID 24487961, PMID 24563480, PMID 24737778, PMID 24810181, PMID 24898549, PMID 25113756, PMID 25253045, PMID 25260842, PMID 25377157, PMID 25403217, PMID 25761639, PMID 26073352, PMID 26084989, PMID 26155941, PMID 26179200, PMID 26655846, PMID 26689566, PMID 27329247, PMID 27764686, PMID 28158463, PMID 28222073, PMID 28665051, PMID 28817753, PMID 28932928, PMID 28939558, PMID 29037983, PMID 29059492, PMID 29510739, PMID 29551775, PMID 29563138, PMID 29603015, PMID 29660598, PMID 29954840, PMID 29980894, PMID 30018133, PMID 30213452, PMID 30457897, PMID 30478190
2023 (25), 2019 (11), 2016 (10), 2025 (10), 2015 (9), 2018 (8), 2009 (4), 2014 (3), 2008 (2), 2017 (2), 2004 (1), R21CA131820 (1), U01CA154967 (1)